Adenomyosis as a prognostic factor in ovarian cancer: a retrospective study

Gozde Sahin, Gözde Şahin, Işıl Turan Bakırcı, Isil Turan Bakirci, Isik Sozen, Işık Sözen, Sinem Özşahin Kiliç, Sinem Ozsahin Kilic, Selim Afsar, Selim Afşar, Nilufer Cetinkaya Kocadal, Nilüfer Çetinkaya, Ipek Geyikoglu
Archives of gynecology and obstetrics · 2025 · vol. 312(2) , pp. 403–412 · doi:10.1007/s00404-025-08023-5 · PMID:40240534 · PMC12334368 · W4409501405
article OA: gold CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Adenomyosis in ovarian cancer patients correlated with earlier stage, lower-grade tumors, endometrioid histology, and improved disease-free survival, particularly in high-grade cases.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This retrospective study analyzed 226 surgically treated ovarian cancer patients (2020–2023) and compared clinicopathologic features and survival outcomes between those with histopathologically confirmed adenomyosis (n=114) and those without (n=112), using a median follow-up of 36 months. Patients with adenomyosis had more favorable characteristics, including more early-stage and lower-grade tumors, smaller tumor sizes, and an association with endometrioid histology (and lower odds of serous carcinoma); disease-free survival at 3 years was significantly better in the adenomyosis group, especially among high-grade tumors. Overall survival did not differ significantly, though high-grade tumors with adenomyosis showed improved overall survival; the paper’s main limitation is its retrospective design and limited follow-up duration (and the sample size reflects the single-center case availability). This paper is centrally about adenomyosis — it examines adenomyosis as a prognostic factor in ovarian cancer.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: Adenomyosis is a gynecological condition that frequently coexists with gynecological malignancies and has been shown to influence disease outcomes. However, its impact on ovarian cancer prognosis remains unclear. This study aimed to investigate the relationship between adenomyosis and clinicopathological and prognostic features in ovarian cancer patients. METHODS: We retrospectively analyzed 226 patients with ovarian cancer who underwent surgery between 2020 and 2023. The patients were divided into two groups based on the presence (n = 114) or absence (n = 112) of adenomyosis, confirmed by histopathological examination. Clinicopathological characteristics, including histological subtypes, disease-free survival (DFS), and overall survival (OS) were compared between the groups with a median follow-up of 36 months. RESULTS: Patients with adenomyosis demonstrated more favorable characteristics, including early stage disease (54.3% vs 39.2%, p = 0.048), lower-grade tumors (55.2% vs 31.2%, p = 0.049), and smaller tumor sizes (39.4% vs 26.7%, p = 0.043). Adenomyosis was significantly associated with endometrioid subtype (OR = 2.89, p = 0.043) and negatively associated with serous carcinoma (OR = 0.39, p = 0.034). Three-year DFS was significantly better in the adenomyosis group (79.2% vs 73.9%, p = 0.01), particularly in high-grade tumors (80% vs 58%, p < 0.05). No significant difference was observed in overall OS (73.3% vs 73.1%, p = 0.14), although high-grade tumors with adenomyosis showed improved OS (71% vs 57%, p < 0.05). CONCLUSION: The presence of adenomyosis in patients with ovarian cancer was associated with favorable clinicopathological features, particularly endometrioid histology and low-grade tumors, and improved survival in high-grade tumors. These findings suggest a potential biological interaction between adenomyosis and ovarian cancer that warrants further investigation for personalized treatment approaches.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (16)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pmc
last seen: 2026-05-13T20:22:03.195721+00:00
pubmed
last seen: 2026-06-11T06:16:30.821809+00:00
License: CC0 · commercial use OK